In the case of Sezary syndrome, a rare form of cutaneous T-cell lymphoma, administration of human TNFR2 antagonistic antibodies led to the rapid death of TNFR2+ tumor cells and TNFR2+ Tregs with an increase in the T-effector cell fraction in experiments in vitro and ex vivo [128]. The gene discussed is TNFRSF1B; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.